Literature DB >> 26646522

DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.

Guido H Jajamovich1, Wei Huang2, Cecilia Besa1, Xin Li2, Aneela Afzal2, Hadrien A Dyvorne1, Bachir Taouli3.   

Abstract

OBJECTIVE: To quantify hepatocellular carcinoma (HCC) perfusion and flow with the fast exchange regime-allowed Shutter-Speed model (SSM) compared to the Tofts model (TM).
MATERIALS AND METHODS: In this prospective study, 25 patients with HCC underwent DCE-MRI. ROIs were placed in liver parenchyma, portal vein, aorta and HCC lesions. Signal intensities were analyzed employing dual-input TM and SSM models. ART (arterial fraction), K (trans) (contrast agent transfer rate constant from plasma to extravascular extracellular space), ve (extravascular extracellular volume fraction), kep (contrast agent intravasation rate constant), and τi (mean intracellular water molecule lifetime) were compared between liver parenchyma and HCC, and ART, K (trans), v e and k ep were compared between models using Wilcoxon tests and limits of agreement. Test-retest reproducibility was assessed in 10 patients.
RESULTS: ART and v e obtained with TM; ART, ve, ke and τi obtained with SSM were significantly different between liver parenchyma and HCC (p < 0.04). Parameters showed variable reproducibility (CV range 14.7-66.5% for both models). Liver K (trans) and ve; HCC ve and kep were significantly different when estimated with the two models (p < 0.03).
CONCLUSION: Our results show differences when computed between the TM and the SSM. However, these differences are smaller than parameter reproducibilities and may be of limited clinical significance.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver; MRI

Mesh:

Substances:

Year:  2015        PMID: 26646522      PMCID: PMC5175209          DOI: 10.1007/s10334-015-0513-4

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  62 in total

1.  Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology.

Authors:  Thomas E Yankeelov; William D Rooney; Wei Huang; Jonathan P Dyke; Xin Li; Alina Tudorica; Jing-Huei Lee; Jason A Koutcher; Charles S Springer
Journal:  NMR Biomed       Date:  2005-05       Impact factor: 4.044

Review 2.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

3.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics.

Authors:  G J Parker; J Suckling; S F Tanner; A R Padhani; P B Revell; J E Husband; M O Leach
Journal:  J Magn Reson Imaging       Date:  1997 May-Jun       Impact factor: 4.813

4.  Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours.

Authors:  Matthew R Orton; Keiko Miyazaki; Dow-Mu Koh; David J Collins; David J Hawkes; David Atkinson; Martin O Leach
Journal:  Phys Med Biol       Date:  2009-03-17       Impact factor: 3.609

5.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

Authors:  O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

Review 6.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 7.  Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.

Authors:  Georgios S Papaetis; Kostas N Syrigos
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

Review 8.  Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

Authors:  Anwar R Padhani
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

9.  Poorly versus moderately differentiated hepatocellular carcinoma: vascularity assessment by computed tomographic hepatic angiography in correlation with histologically counted number of unpaired arteries.

Authors:  Yoshiki Asayama; Kengo Yoshimitsu; Hiroyuki Irie; Yunosuke Nishihara; Shinichi Aishima; Tsuyoshi Tajima; Masakazu Hirakawa; Kousei Ishigami; Daisuke Kakihara; Akinobu Taketomi; Hiroshi Honda
Journal:  J Comput Assist Tomogr       Date:  2007 Mar-Apr       Impact factor: 1.826

10.  Quantitative liver MRI combining phase contrast imaging, elastography, and DWI: assessment of reproducibility and postprandial effect at 3.0 T.

Authors:  Guido H Jajamovich; Hadrien Dyvorne; Claudia Donnerhack; Bachir Taouli
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

View more
  13 in total

1.  Dynamic Contrast-Enhanced MRI-Derived Intracellular Water Lifetime (τ i ): A Prognostic Marker for Patients with Head and Neck Squamous Cell Carcinomas.

Authors:  S Chawla; L A Loevner; S G Kim; W-T Hwang; S Wang; G Verma; S Mohan; V LiVolsi; H Quon; H Poptani
Journal:  AJNR Am J Neuroradiol       Date:  2017-11-16       Impact factor: 3.825

2.  Estimation of cellular-interstitial water exchange in dynamic contrast enhanced MRI using two flip angles.

Authors:  Jin Zhang; Sungheon Gene Kim
Journal:  NMR Biomed       Date:  2019-07-26       Impact factor: 4.044

3.  Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.

Authors:  Daniel Stocker; Stefanie Hectors; Octavia Bane; Naik Vietti-Violi; Daniela Said; Paul Kennedy; Jordan Cuevas; Guilherme M Cunha; Claude B Sirlin; Kathryn J Fowler; Sara Lewis; Bachir Taouli
Journal:  Eur Radiol       Date:  2021-05-27       Impact factor: 5.315

4.  Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Po-Chin Liang; Chiun Hsu; Chih-Hung Hsu; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2016-12-12       Impact factor: 5.315

5.  Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study.

Authors:  Marta Campos; Isabel Candelária; Nickolas Papanikolaou; Adélia Simão; Carlos Ferreira; Georgios C Manikis; Filipe Caseiro-Alves
Journal:  GE Port J Gastroenterol       Date:  2019-02-18

6.  Combination of DCE-MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma.

Authors:  Changmin Liu; Roger Sun; Jing Wang; Fangling Ning; Zhenbo Wang; Judong Luo; Shaoshui Chen; Shuanghu Yuan
Journal:  Biomed Res Int       Date:  2020-06-16       Impact factor: 3.411

7.  Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience.

Authors:  Stefanie J Hectors; Mathilde Wagner; Cecilia Besa; Wei Huang; Bachir Taouli
Journal:  Contrast Media Mol Imaging       Date:  2018-10-03       Impact factor: 3.161

8.  Reliability of dynamic contrast-enhanced magnetic resonance imaging data in primary brain tumours: a comparison of Tofts and shutter speed models.

Authors:  Marianna Inglese; Katherine L Ordidge; Lesley Honeyfield; Tara D Barwick; Eric O Aboagye; Adam D Waldman; Matthew Grech-Sollars
Journal:  Neuroradiology       Date:  2019-08-07       Impact factor: 2.804

9.  Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Authors:  Stefanie J Hectors; Mathilde Wagner; Octavia Bane; Cecilia Besa; Sara Lewis; Romain Remark; Nelson Chen; M Isabel Fiel; Hongfa Zhu; Sacha Gnjatic; Miriam Merad; Yujin Hoshida; Bachir Taouli
Journal:  Sci Rep       Date:  2017-05-26       Impact factor: 4.996

Review 10.  Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma.

Authors:  Davide Ippolito; Riccardo Inchingolo; Luigi Grazioli; Silvia Girolama Drago; Michele Nardella; Marco Gatti; Riccardo Faletti
Journal:  World J Gastroenterol       Date:  2018-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.